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Ly6Chi inflammatory monocytes develop in the bone marrow and migrate to the site of
infection during inflammation. Upon recruitment, Ly6Chi monocytes can differentiate
into dendritic cells or macrophages. According to the tissue environment they can also
acquire different functions. Several studies have described pre-activation of Ly6Chi
monocytes in the bone marrow during parasitic infection, but whether this process
occurs during experimental visceral leishmaniasis and, if so, the mechanisms
contributing to their activation are yet to be established. In wild type C57BL/6 (B6)
mice infected with Leishmania donovani, the number of bone marrow Ly6Chi
monocytes increased over time. Ly6Chi monocytes displayed a highly activated
phenotype from 28 days to 5 months post infection (p.i), with >90% expressing
MHCII and >20% expressing iNOS. In comparison, in B6.Rag2-/- mice <10% of bone
marrow monocytes were MHCII+ at day 28 p.i., an activation deficiency that was
reversed by adoptive transfer of CD4+ T cells. Depletion of CD4+ T cells in B6 mice and
the use of mixed bone marrow chimeras further indicated that monocyte activation
was driven by IFNg produced by CD4+ T cells. In B6.Il10-/- mice, L. donovani infection
induced a faster but transient activation of bone marrow monocytes, which correlated
with the magnitude of CD4+ T cell production of IFNg and resolution of the infection.
Under all of the above conditions, monocyte activation was associated with greater
control of parasite load in the bone marrow. Through reinfection studies in B6.Il10-/-
mice and drug (AmBisome®) treatment of B6 mice, we also show the dependence of
monocyte activation on parasite load. In summary, these data demonstrate that during
L. donovani infection, Ly6Chi monocytes are primed in the bone marrow in a process
driven by CD4+ T cells and whereby IFNg promotes and IL-10 limits monocyte
activation and that the presence of parasites/parasite antigen plays a crucial role in
maintaining bone marrow monocyte activation.
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INTRODUCTION
The bone marrow (BM) is the major site for hematopoiesis in
adult mammals, producing all major cell lineages from a pool of
committed precursors. Ly6Chi monocytes are derived from a
common myeloid progenitor, through intermediates that include
monocyte-dendritic cell progenitors and granulocyte-monocyte
progenitors (1), and with cell fate specified by the transcription
factors PU.1, IRF1 and Klf4 as well as by the action of key
hematopoietic growth factors such as CSF-1 (2). Ly6Chi
monocytes are released into the bloodstream and migrate to
peripheral organs in normal and inflammatory conditions where
they contribute to a wide range of physiological and pathological
processes including innate and adaptive immune responses,
tissue remodeling and tissue repair [reviewed in (3)].
Ly6Chi monocytes are highly plastic and depending on the
environment, they can differentiate into a variety of cells
including macrophages and dendritic cells (DCs) or maintain a
monocyte phenotype (4, 5). It is unclear, however, whether such
terminal differentiation only occurs once in the peripheral tissues
or is initiated earlier during BM residency. For example,
specialized monocyte progenitors have been demonstrated in
the BM and reflect later polarization of monocyte function in the
periphery (6). In addition, Ly6Chimonocytes have the capacity to
respond to microbial stimuli during their development in the BM
before their egress into the peripheral circulation and their
tissue-specific functions are in part pre-programmed (7).
Specifically, infection with Toxoplasma gondii led to the
secretion of interferon-g (IFNg) by NK cells and this cytokine
was responsible for monocyte priming and the development of
regulatory capacity (7, 8). These and other studies (1, 6, 9, 10)
collectively suggest that Ly6Chi monocytes may become
functionally committed prior to their arrival at sites of tissue
inflammation or infection.
Although it is known that Ly6Chi monocytes play an
important role against various intracellular parasites, the extent
to which they contribute to the immune response against
different species of Leishmania is still unclear, with the data
often seemingly contradictory. During L. major infection, Ly6Chi
monocytes have been demonstrated to have a dual role, on the
one hand aggravating during primary infection and on the other
hand being protective during secondary infection (11). This
latter function reflects their ability to facilitate rapid
recruitment of CD4+ T cells at the secondary site of infection
and hence to enhance parasite elimination. Others have
demonstrated, however, that monocyte-derived DCs are
essential for priming protective Th1 response in L. major
infected mice (12). The situation is further complicated in
models of visceral leishmaniasis, where parasites accumulate
predominantly in spleen, liver and BM (13). Monocytes
accumulate in the spleen throughout the course of L. donovani
infection and play a role in tissue remodeling (14). Several
studies have shown that in absence of Ly6Chi monocytes,
B6.Ccr2-/- mice fail to generate an effective early Th1 response
allowing for a rise in tissue parasite burden load. More recently, a
pathogenic role for Ly6Chi monocytes in promoting parasite
survival was demonstrated, a finding supported by the
observation that emergency hematopoiesis during L. donovani
infection leads to the differentiation of Ly6Chi monocytes into
regulatory monocytes in the BM that contribute to parasite
survival (15). Given that the BM acts as a site of infection, T
cells are also recruited in high numbers and we have previously
demonstrated that TNF-dependent CD4+ IFNg+ T cells
accumulate in significant numbers in the BM resulting in
progressive hematopoietic stem cell exhaustion (16) and
erosion of the erythropoietic niche (17). However, the impact
of these highly pathogenic CD4+ T cells on local monocyte
activation has not previously been determined.
In this study, therefore, we used a combination of gene
targeted mice, mixed chimeras, antibody deletion and drug
treatment to explore the mechanisms underpinning BM Ly6Chi
monocyte activation during L. donovani infection, and uncover
its relationship to BM CD4+ T cells, the production of the
cytokines IFNg and IL-10, and parasite load.
MATERIALS AND METHODS
Animals and Infection
B6.CD45.1 (B6.Ptprca) , B6.CD45.2 (B6.Ptprcb) and
B6.CD45.2.Rag2-/- mice used in this study were bred and
maintained under specific-pathogen free (SPF) conditions at
the Biological Services Facility, University of York. BM cells
from mice lacking the Ifngr1 gene (B6.Ifngr1-/-) on a B6
background were obtained from the Jackson Laboratory. All
mice were between 5–8 weeks of age at the start of experimental
work. Mice were infected via the lateral tail vein with 3x107
amastigotes of the Ethiopian strain of L. donovani (LV9). To
assess the impact of drug-induced parasite clearance, mice were
treated once with 10 mg/kg Amphotericin B (AmBisome®) at
day 28 post-infection and killed 72 hours later. Animals were
killed by CO2 asphyxia and cervical dislocation at the time points
specified. Spleen and liver parasite burden was expressed as
Leishman-Donovan units (LDU), where LDU was equal to the
number of parasites/1000 host nuclei multiplied by the organ
weight in milligrams. BM parasite burden was determined by
limiting dilution assay (LDA). Briefly, two-fold serial dilutions in
96-well flat bottom microtiter plates were performed in OMEM
medium supplemented with 20% FCS. The plates were scored
microscopically for growth and the number of parasites in each
tissue was determined from the highest dilution at which
parasites could be grown out after 7–14 days incubation at 26°C.
Cell Extraction
The spleen was mechanically disrupted and incubated in RPMI
with 0.25 mg/ml Collagenase IV and 0.1 mg/ml DNase 1 for
30min at RT. Spleen tissue was then forced through a 70µm
strainer to obtain a single cell suspension. Cell pellets were
resuspended in ACK Lysing buffer (5min at RT) then washed
with RPMI. BM cells from tibias were flushed with a 26g needle
and cold RPMI. To obtain a single cell suspension, cells were run
through a 70µm cell strainer and spun down. Cell pellets were
resuspended in ACK lysing buffer for 5min at RT and washed.
Cells were resuspended in RPMI 1640 medium (Life
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Technologies) supplemented with 10% heat-inactivated FCS,
4 mM L-glutamine, 10 mM HEPES, 100 U/ml penicillin and
100 mg/ml streptomycin and kept on ice. Cells were counted with
trypan blue under a light microscope.
Flow Cytometry and Cell Sorting
For immunolabelling, cells were washed and labelled with LIVE/
DEAD Fixable Dead Cell Stains (Thermo Fisher Scientific) to
exclude dead cells. Cells were incubated with anti-Fc III/II
(CD16/32) receptor Ab (2.4G2), followed by surface staining
with various combination of the following antibodies for 30min
at 4°C in the dark: CD11b (M1/70), Ly6G (1A8); Sca1 (D7),
CD45 (30-F11), CD45.1 (A20), CD45.2 (104), CD3e (145-2C11
and UCHT1), CD4 (RM4-5 and 4SM95), CD8b (H35-17.2),
TCR-b (145-2C11), CD11c (N418), Ly6C (HK1.4), MHC-II
(M5/114.15.2), MerTK (2B10C42), CD40 (XX), CD80 (XX),
CD86 (GL-1), CD64(X54-5/7.1). Staining for CCR2 employed
AlexaFluor 700 anti-CCR2 (475301) and was done prior to
surface staining at 37°C for 20-30min.
In some experiments, cells were stimulated with Brefeldin A
at 10µg/ml alone or in combination with Phorbol-12-myristate-
13-acetate (PMA) (Sigma-Aldrich) and ionomycin (Sigma-
Aldrich) for 4h at 37°C, then fixed and permeabilized with the
eBioscience™ Intracellular Fixation & Permeabilization Buffer
Set according to the manufacturer instructions and stained for
IL-10 (JES5-16E3), NOS2 (CXNFT), TNF (MP6-XT22) and
IFNg (XMG1.2).
All Abs were from eBiosciences, BD Biosciences, Biolegends
or R&D systems. Data were collected using FACSDiva software
on BD LSR Fortessa X-20 (BD Biosciences), and analyzed using
FlowJo software (TreeStar). Forward-scatter and side-scatter
width was employed to exclude cell doublets from analysis.
Cell sorting to > 95% purity was performed on a MoFlo
Astrios (Beckman Coulter).
Mixed Bone Marrow Chimeras and
Adoptive T Cell Transfer
BM cells were purified as described previously. B6.CD45.1
recipient mice were irradiated with 850 rad from an X-ray
source using a two split dose regimen and reconstituted with
106 cells from B6.CD45.1 and B6.Ifngr1-/-.CD45.2 mice admixed
in a 50:50 ratio. Mice were maintained on oral antibiotics for the
first 6 weeks post reconstitution. Mice were infected at 7 weeks of
chimerism and killed 28 days after the infection. For T cell
adoptive transfer, B6.Rag2-/- CD45.2 mice infected for 21 days
received 106 CD4+ or CD8+ T cells isolated from the BM of 28
day-infected B6.CD45.1 mice. Mice were killed 7 days post-
transfer for analysis.
Treatment With Anti-IL10R, Anti-CD4
Monoclonal Antibody
CD4+ T cells were depleted by administering 400 mg of
InViVoMAb anti-mouse CD4 (clone GK1.5) intra-peritoneally,
twice weekly beginning on day 14 post-infection and for 2 weeks.
Control mice were injecting with the same amount and at the
same frequency with InVivoMAb rat IgG2b isotype control
(anti-keyhole limpet hemocyanin; LTF-2). IL-10 signaling was
blocked by injecting 250mg of InVivoMAb anti-mouse IL-10R
(clone 1B1.3A; CD210) intraperitoneally every 3 days for 14 days
starting on day1 post-infection. InViVoMAb rat IgG1 Isotype
control (anti-trinitophenol; TNP6A) was administered to control
mice. All antibodies and isotype controls were purchased from
BioXcell (Lebanon, USA).
Statistical Analysis
Prior to applying appropriate statistical tests, parametric test
assumptions were assessed. Normality of data distribution was
based on Shapiro-Wilks test. Further, due to small sample n, data
skewness and kurtosis were analyzed to confirm or dispute
results from Shapiro-Wilks test. Where data did not comply
with a normal distribution, a Log10-transformation was applied
prior to test application, if that resulted in data normality.
Homogeneity of sample variance was analyzed by F test (2
samples) or by Levene’s test (>2 samples). All groups analyzed
were independent of one another, including data in time courses
as different mice were harvested at each time point. To conform
with the assumption of data continuity, proportional data (%)
were converted by the arcsin conversion prior to test application
as proposed by Sokal and Rohlf (18). Experimental group n refers
to the number of mice per group and are stated in the respective
figure legends. Where unequal sample size occurred, the smallest
n is stated as the power calculation always relies on the smallest
group n.
For two sample tests, Welch’s version of the t test was chosen
for its greater robustness. As a non-parametric alternative, a
Mann-Whitney test was applied. For >2 sample one-way tests,
Welch’s version of the ANOVA was chosen for its greater
robustness under minor departure from variance homogeneity.
Alternatively, Brown-Forsythe’s version of the ANOVA was
chosen where also mild to moderate data skewness was
observed. As post hoc multiple comparison test, we used
Dunnett’s T3 test. As a non-parametric alternative, the
Kruskal-Wallis test was chosen. As a post hoc test, we used
Dunn’s MCT test. For non-parametric two-way factorial design
analysis, we used the ‘t2wat’ function from the ‘WRS2’ package
in R (19) which used trimmed means for greater robustness. As a
post-hoc multiple comparison test, we used the ‘emmeans’
function from the ‘emmeans’ package in R (20), which makes
use of estimated marginal means (EMM). Applied tests are stated
together with cited p-values and the respective figure legends
along with other statistics. Statistical significance was set as a =
0.05. Statistical power was retro-assessed by using the ‘pwr.t.test’
and ‘pwr.t2n.test’ functions from the ‘pwr’ package for 2 sample
comparisons (21), the ‘pwr.1way’ function for >2 sample one-
way comparisons and the ‘pwr.2way’ function for two-way
factorial analysis, both from the ‘pwr2’ package for R (22).
All statistical tests were applied either in GraphPad PRISM
v.9.1.0 or in R v.4.1.0 using RStudio v. 1.4.1717. In addition to the
previously cited ‘WRS2’, emmenas’, ‘pwr’ and ‘pwr2’ packages,
the following R packages were used: ‘readxl’ (23), ‘xlsx’ (24), ‘rlist’
(25), ‘janitor’ (26), ‘rstatix’ (27), ‘car’ (28), ‘moments’ (29),
‘reshape2’ (30), ‘effectsize’ (31) and ‘tidyverse’ (32).
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RESULTS
Inflammatory Monocytes Are Primed in
the BM of B6 but Not B6.Rag2-/- Mice
During L. donovani Infection
The activation of monocytes in the BM during infection has yet
to be explored in the context of L. donovani infection. In contrast
to infection of immunocompetent B6 mice, infection in
B6.Rag2-/- mice was characterized by delayed hepato-
splenomegaly and unchecked parasite growth in spleen, liver
and BM over a 5 month period (Figures 1A–C). Inflammatory
monocytes (iMo), defined as CD45+CD11b+Ly6G-Ly6ChiCCR2+
cells (Figure 1D), decreased in number early after infection, as
noted by others (15), but then transiently increased in number in
the BM of B6 mice being ~2-fold higher in absolute number at 28
day p.i compared to day 0 and ~3.5 fold increased compared to
d4. In contrast in B6.Rag2-/- mice, no early decline in absolute
monocyte numbers was noted early after infection and a
transient ~2 fold increase was observed at d28 (Figure 1E). To
determine whether these iMo were found in a primed state, we
analysed expression of MHCII and iNOS (7) over the course of
infection. MHCII expression was low in both strains of mice for
the first 14 days p.i. and increased from d28 p.i., with marked
differences between B6 and B6.Rag2-/- mice (Figures 1F, G). In
B6 mice, MHCII was abundant on almost all BM monocytes
from d28 p.i. onwards whereas in B6.Rag2-/- mice, only 20% of
monocytes expressed MHCII at later time points, with statistical
difference reached at day 28, day 56 and day 152 (p<0.0001)
between B6 and B6.Rag2-/- mice. This lack of activation in
immunodeficient mice was even more evident when measuring
intracellular iNOS (Figure 1H). These data suggest that iMo are
primed in the BM during L. donovani infection and that adaptive
immunity is required to drive this response. Furthermore, as
infection is controlled in B6 mice, the extent of BM monocyte
activation as measured by iNOS generation wanes, despite
maintenance of high MHCII expression.
CD4+ T Cells Are the Main Producers of
IFNg and Drive BM Monocyte Activation in
an IFNg-Dependent Manner
IFNg has been described as a key cytokine controlling monocyte
activation. To identify probable sources of IFNg in the BM of L.
donovani-infected mice, we stimulated BM leucocytes at different
times p.i. with PMA and Ionomycin. Approximately 60-70% of
CD4+ T cells had the capacity to produce IFNg at d28 and these
cells persisted to 8wks p.i [(16) and Figure 2A]. In contrast,
~ 30% of CD8+T cells were capable of producing IFNg at d28 p.i.
and this frequency declined thereafter. No IL-10 production was
observed by either CD4+ or CD8+ BM T cells under these
stimulation conditions (Figure 2A). CD4+ T cells represented
~75% of all IFNg+ cells in the BM of B6 mice at d28 (p < 0.0001)
Figure 2B). Of note, the expansion of IFNg-producing CD4+ T
cells preceded that of MHCII expression on iMo (Figure 2C),
suggesting a causal relationship. To address this directly, we used
an adoptive transfer model in B6.Rag2-/- recipients (Figure 2D).
Adoptively-transferred CD4+ isolated from d28-infected B6 mice
retained their capacity to produce IFNg in B6.Rag2-/- hosts
(Figure 2E) and induced MHCII expression on recipient BM
iMo as shown by the significant increase in MHCII expression in
infected B6.Rag2-/-mice receiving CD4+ T cells vs infected
B6.Rag2-/- mice (p < 0.0001) (Figures 2F, G). In contrast,
CD8+ T cells produced less IFNg after adoptive transfer and no
significant differences were found between the percentage of
MHCII+ iMo cells in infected B6.Rag2-/- mice receiving CD8+ T
cells vs infected B6.Rag2-/- (Figures 2E–G). Importantly, transfer
of CD4+ T cells into a naïve B6.Rag2-/- mice did not lead to BM
iMo activation, ruling out an effect due to homeostatic T cell
expansion (Figure S1) and demonstrating a requirement for
cognate antigen recognition in vivo. The origin of CD4+ T cells
(naïve versus d28 infected B6 mice) did not change the outcome
of the experiments (Figure S1).
To independently confirm the role of CD4+ T cells in iMo
activation, we used the alternate approach of depleting CD4+ T
cells from immunocompetent mice. We depleted CD4+ cells in
infected B6 mice from day 14 p.i to d28 p.i. with anti-CD4
depleting antibody, the time frame over which iMO MHCII
expression increases (Figure 2C). After CD4+ T cell depletion,
the frequency of total BM cells producing IFNg in the BM,
measured directly ex vivo, was reduced by approximately 70%
(0.8% vs 2.8% in anti-CD4 treated vs. control mice (p=0.0079);
Figure 3A). Although depletion was incomplete, we observed a
reduction in MHCII expression in iMo reflected in both the
percentage of MHCII+ cells, (p=0.0027 and p=0.0036
respectively) (Figures 3B, C) and in median fluorescent
intensity of expression (Figure 3D). Of note, parasite load in
the BM of the mice treated with anti-CD4 mAb was increased
compared to control mice, (p=0.0082) (Figure 3E), indicating
that the reduction in CD4+ T cells and presumably IFNg
production had a significant impact on host resistance to
L. donovani. This is supported by the observation of a
significant decrease of parasite number in the BM of adoptively
transferred B6.Rag2-/- mice as compared to their control
(Figure S2).
Finally, in order to verify that BM iMo respond directly to
IFNg, we used a mixed chimera model. Irradiated B6.CD45.1
mice were reconstituted with B6.CD45.1 and B6.Ifngr1-/-.CD45.2
BM cells in a 1:1 ratio (Figure S3A). At day 28 p.i, CD45.1+ (wild
type) but not CD45.2+ (Ifngr1-/-) iMo were primed in the BM, as
determined by expression of MHCII (p=0.0079; Figures 3F, G).
Ifngr1-/- iMo also produced minimal levels of NOS2 and TNF
compared to wild type iMo in these IFNg-sufficient mixed
chimeras (Figure 3H). As expected, Ifngr1-/- and wild type
CD4+ T cells produced equivalent amount of IFNg in the BM
(Figure S3B). Collectively, these data indicate that BM CD4+ T
cells produce IFNg and that IFNg signaling on BM iMo is
necessary to induce their activation in L. donovani infected mice.
IL-10 Inhibits iMo Activation and Restrains
Parasite Elimination
Having demonstrated the main pathway related to iMO
activation in the BM of L. donovani-infected mice, we next
wished to determine whether this was constrained in any way
by regulatory cytokine production. Although IL-10 has been long
Romano et al. Monocyte Activation in Visceral Leishmaniasis







FIGURE 1 | Monocytes are activated during L. donovani infection in B6 but not in B6.Rag2-/- mice. (A, B) Weight (left panel) and Leishman Donovan Unit (right
panel) in the spleen (A) and liver (B) of B6 mice and B6.Rag2-/- at different time point during the course of the infection. Two-way factorial analysis applied to LDUs in
(A, B): Spleen P=0.001, Liver P=0.001; statistical power: Spleen 94%, Liver 99%; n≥7; post hoc test EMM: statistical difference reached in spleen and liver at day 56
and day 152 (P<0.0001; ****). (C) Parasite load per one million cells in the bone marrow measured by limiting dilution assay. Two-way factorial analysis applied:
P=0.09; statistical power: 32.3%; n≥3; post hoc test EMM: statistical difference reached at day 152 (P<0.0001;****). (D) Gating strategy to identify Ly6C monocytes
in BM. (E) Absolute number of iMo cells per femur. Two-way factorial analysis applied: P=0.165; statistical power: 98.5%; n≥7; post hoc test EMM: statistical
difference reached at day 28, day 56 and day 152 (*; P=0.014, P=0.036 and P=0.046), respectively. (F, G) MHCII expression on BM Ly6C+CCR2+ cells shown as
percentage (F) and as representative flow histogram plots (G) in B6 and B6.Rag2-/- mice during the course of the infection. Two-way factorial analysis applied in (F):
P=0.001; statistical power: 99%; n=4; post hoc test EMM: statistical difference reached at day 28, day 56 and 152 (P<0.0001; ****). (H) iNOS and MHCII expression
on Ly6C+CCR2+ monocytes. Data are derived from analysis of 8 to 10 individual mice (4 to 5/experiment) of each strain at each time point pooled from two
independent experiments and are shown as mean ± SD. Data in (G, H) are representative plots, including lower and upper range of MHCII expression at day 14. In
(A–F) median with 95% CI is shown.
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implicated as a negative regulator of macrophage activation in
multiple other settings (33), its role in iMO activation is not
known. As BMCD4+ T cells did not produce demonstrable IL-10
after in vitro restimulation (Figure 2A), we used B6.Il10-/- mice
to evaluate the possible role of IL-10 in regulating IFNg-mediated
iMO activation (Figure 4). B6.Il10-/- mice have previously been
shown to be resistant to L. donovani infection in terms of liver
and spleen parasite loads (34). In BM, B6.Il10-/- mice had
reduced parasite load at all time points measured (Figure 4A)
and at d56 parasites were undetectable in the BM of B6.Il10-/-
mice when measured by LDA. We then measured iMO
activation by MHCII and iNOS expression. At d14 p.i.,
18.9% ± 11.2 of iMo in B6.Il10-/- mice were NOS2+ compared
to 0.85% ± 1.54 in B6 mice (p=0.0077; Figure 4F). Similarly,
98.5% ± 6.0 of iMo in B6.Il10-/- mice expressed MHCII
compared to 42.85% ± 12.73 in B6 mice (p<0.0001;
Figure 4E). MHCII MFI was also significantly increased in
B6.Il10-/- mice (p=0.0003; Figure 4D). Together, these data
indicate a more rapid kinetic for iMo activation in the absence
of IL-10 (Figures 4B–F). Nevertheless, at d28 p.i., iMO
activation for iNOS production was similar in the presence or
absence of IL-10 (22.7 ± 15.0 vs. 19.8 ± 13.4, respectively;
p=0.989) as was MHCII expression (97.8 ± 2.7 vs. 90.5 ± 10.6;
p=0.522; Figure 4E, F). Surprisingly, whereas iMo activation was
sustained in wild type mice at d56 p.i., it was reduced at this later





FIGURE 2 | CD4+ T cells are the main producers of IFNg in the bone marrow of B6 mice and contribute to local monocyte activation. (A) Dot plot indicating
representative expression of IL-10 and IFNg by CD3+CD4+ T cells at different time points p.i. Cells were stimulated with PMA/Ionomycin. (B) Percentage of CD4+ T
cells expressing IFNg. Welch’s t test applied: P<0.0001 (****); 95% CI: 38.89 – 51.63; statistical power: 100%; n≥4. (C) IFNg expression by BM CD4+ T cells and
MHCII expression on Ly6C+CCR2+ monocytes. Data was normalized by subtraction of d0 mean after arcsin conversion, respectively. (D) Protocol for adoptive
transfer of T cells. (E) Cytokine production by adoptively transferred BM CD4+ or CD8+ T cells 1 week post transfer into recipient L. donovani-infected B6.Rag2-/-
mice. Cells were stimulated with PMA/Ionomycin. (F, G) MHCII expression on Ly6C+CCR2+ monocytes in the BM of the mice one week post adoptive T cell transfer,
shown as histogram plots (F) and percentage (G). Data are derived from analysis of 3 to 4 individual mice of each strain per group and are shown as mean ± SD.
Data are pooled from 2 independent experiment. Brown-Forsythe ANOVA applied in (G) without group B6.wt NA: P<0.0001 (****); statistical power: 100%; n≥4; post
hoc test Dunnett’s T3, the different pairwise comparisons are shown in Table S1. Data in (E, F) are representative plots.
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MHCII+ cells (94.7 ± 6.0 vs. 40.0 ± 13.9; p<0.0001; Figure 4E). In
contrast, iNOS production declined at a similar rate in both B6
mice and IL-10-deficient mice (8.0 ± 5.1 vs. 1.5 ± 5.1%
respectively; p=0.73; Figure 4F).
As parasites were no longer detectable at d56 p.i in B6.Il10-/-
mice (Figure 4A), we hypothesized that the presence of parasites
may be necessary to maintain iMo activation status, providing an
antigen depot to allow continued stimulation of IFN-producing
CD4+ T cells. To test this hypothesis, we measured the level of
IFNg production by CD4+ T cells at d14 and d56 p.i in the BM of
B6 and B6.Il10-/- mice (Figures 4G–J). At d14 p.i., CD4+ T cells
from B6.Il10-/- mice showed a trend towards greater IFNg
production compared to B6 mice after both polyclonal
stimulation (Figures 4G, H) and more strikingly directly
ex vivo (Figures 4I, J). In contrast, at d56 p.i., this situation
was reversed, again more strikingly with direct ex vivo
measurement of IFNg (p=0.0003 and p=0.0032, respectively)
(Figures 4H, J). These data suggest that IL-10 initially restrains
iMo activation, but that at later time points, IL-10 may indirectly
contribute to sustaining the level of iMo activation via
maintenance of parasite load and ongoing effector CD4+ T cell
IFNg production.
To confirm whether early IL-10 restrains iMo activation, we
used the alternate approach of blocking IL-10 signaling in B6
mice by administration of anti-IL-10 receptor antibody for 14
days, starting at day 1 p.i. (Figure 4K). Blockade of IL-10
signaling led to a decrease in parasite load in the BM, as
expected from the results observed in B6.Il10-/- mice although
not significantly (p=0.0717) (Figure 4A), as well as an increase
in iMo activation, as measured by MHCII expression
(Figures 4L, M).
The Presence of Parasites in the BM
Contributes to iMo Activation
To determine whether parasite load/and or antigen availability
plays a role in determining the level of iMo activation, we re-
infected B6.Il10-/-mice at d56 p.i., a time at which they had cleared
their primary infection (Figure 5A). One day post-re-infection,
Leishmania parasites were detected in the BM of re-infected mice
(p=0.006; Figure 5B). Strikingly, BM iMo from these re-infected
mice were highly activated, returning to levels of MHCII
expression seen at d14 p.i. (B6.wt vs. B6.il10-/- RI (P=0.0006)
and B6.il10-/- vs. B6.il10-/- RI (P=0.0002)) (Figures 5C–E).
We then conducted the reciprocal experiment, using the anti-
leishmanial drug AmBisome® to clear parasite load prematurely
in day 28-infected B6 mice. Treatment with Ambisome® for 3
days reduced BM parasite load to less than 10 parasites/106 cells
(p<0.0001; Figure 5F) and the level of activated iMo was reduced
significantly, as determined by a reduction in the frequency of
MHCII+ cells (99.37% ± 0.61 reduced to 71.73% ± 4.63 in control
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FIGURE 3 | Monocytes respond to IFN-g produced by CD4+ T. (A–E) At day 14 p.i, B6.wt mice were injected with an anti-CD4 depleting antibody or a control
antibody for 14 days. All the data shown correspond to BM results. (A) Ex vivo IFNg produced in the BM. Mann-Whitney test applied: P=0.0079 (**); 95% CI:
-8.496 – -2.435; statistical power: 96.3%; n=5. Histogram and bar graph representing the expression (B) and percentage (C) respectively, of MHCII on
Ly6C+CCR2+ monocytes. Welch’s t test applied in (C): P=0.0027 (**); 95% CI: -26.26 – -8.97; statistical power: 99.2%; n=5. (D) MFI of MHCII and CD80 on the
Ly6C+CCR2+ monocytes. Welch’s t test applied in (D): P=0.0036 (**); 95% CI: -1053 – -290.5; statistical power: 99.2%; n=5. (E) Parasite burden measured in
infected B6 at d28 by limiting dilution assay. Welch’s t test applied in (E): P=0.0082 (**); 95% CI: 0.275 – 1.346; statistical power: 86.3%; n=5. (F–H) Naïve lethally
irradiated B6.CD45.1 recipient mice received a 50:50 of BM cells from B6.CD45.1 and B6.Ifngr1-/- CD45.2 mice. Subsequently infected with 3x107 L. donovani
amastigotes for 28 days. (F, G) At day 28, the level of activation of Ly6C+CCR2+ monocytes cells was determined based on the level of expression of MHCII. Mann-
Whitney test applied in G: P=0.0079 (**); 95% CI: -12838 – -8928; statistical power: 100%; n=5. Data are the pool of 5 mice/group/experiment. Mean +/- SD is
shown. (H) Dot plot representative of the production of NOS2 and TNF by CD45.1 or CD45.2 Ly6C+CCR2+ monocytes in the BM.
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FIGURE 4 | Absence of IL-10 changes the kinetics of monocyte activation in the BM. B6 and B6.Il10-/- mice were infected with L.donovani amastioges in the tail vein for
14, 28 and 56 days. Data from the BM are shown (A–G). (A) Parasites burden in the bone marrow determined by limiting dilution assay at the indicated time point. Two-
way ANOVA applied on log10 transformed data: P<0.0001; statistical power: 11.9%%; n≥6; post hoc test Šıd́ák’s MCT: statistical difference reached at day 28 and day
56 (P<0.0001; ****). (B) Dot plot representative of nos2 and MHCII expression by Ly6C+CCR2+ monocytes. (C–F) Histogram (C), bar graph showing MFI (D), percentage
of MHCII (E) and percentage of nos2 (F) on BM Ly6C+CCR2+ monocytes. Two-way factorial analysis applied in (E): P=0.001; statistical power: 8.2%; n≥3; post hoc test
EMM: statistical difference reached at day 14 and day 56 (P<0.0001; ****); and two-way factorial analysis applied in (F): P=0.013; statistical power: 6.1%; n≥4; post hoc
test EMM: statistical difference reached at day 14 (P<0.0077; **). (G, I) Production of IFN-g and TNF by CD4+ T cells in the BM at the different time point post-infection
and (H, J) percentage of IFN-g produced by CD4+ T cells after PMA-Ionomycin-BFA stimulation for 4h (G, H) and ex vivo (BFA stimulation only, (I, J). Brown-Forsythe
ANOVA applied in (H): P<0.0001; statistical power: 43.8%; n≥4; post hoc test Dunnett’s T3: statistical difference reached at day 56 (P=0.0003; ***); 95% CI: 8.16 –
30.46; and Brown-Forsythe ANOVA applied in (J): P=0.0002; statistical power: 47.5%; n≥4; post hoc test Dunnett’s T3: statistical difference reached at day 56
(P=0.0032; **); 95% CI: 4.99 – 24.47. (K–M) B6 mice infected with L. donovani were injected with an anti-IL-10 depleting antibody or the isotype control for 14 days
starting 1 day prior to the infection (K) Parasite load determined by limiting dilution assay in the BM at day 14 p.i. Welch’s t test applied: P=0.0717; 95% CI: -1.86 –
0.115; statistical power: 13.9%; n=5. (L) Percentage and (M) MFI of MHCII expressed on Ly6C+CCR2+ monocytes. Brown-Forsythe ANOVA applied in (L): P<0.0001;
statistical power: 100%; n≥3; post hoc test Dunnett’s T3: statistical difference reached in NA vs. aIL10R (P<0.0001;****; 95% CI: -79.79 – -53.75) and CLT vs. aIL10R
(P<0.0001; ****; 95% CI: -67.77 – -49.41); and Brown-Forsythe ANOVA applied in (M): P=0.0009; statistical power: 100%; n≥3; post hoc test Dunnett’s T3: statistical
difference reached in NA vs. aIL10R (P<0.0034; **; 95% CI: -4367 – -1169) and CLT vs. aIL10R (P<0.0034; **; 95% CI: -4361 – -1175). For (A–J), data are derived from
analysis of 6 to 7 individual mice (2 to 4/experiment) of each strain at each time point pooled from two independent experiments and are shown as mean ± SD. Data in
(B, C, G) and I are representative plots. For (K–M), data are the pool of 5 mice/group/time point. Mean ± SD is shown. Experiment was performed once. In (A, D–F)
median with 95% CI is shown. For (H, J) statistical details are found in Table S1.
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vs drug-treated mice; p<0.0001; Figure 5G) and a reduction in
MFI for MHCII (3619 ± 1360 to 616.3 ± 90.2 in control vs drug-
treated mice; Figure 5H). Thus, forced early reduction in
parasite load is accompanied by reduced iMo activation in IL-
10-sufficient B6 mice.
Collectively, these data suggest a model whereby parasite load
in the BM is an essential driver of CD4+IFNg+ T cell-dependent
iMo activation, and that IL-10 serves to regulate this pathway via
its capacity to regulate macrophage leishmanicidal activity.
DISCUSSION
Our data extend a previous study of BM monocytes that also
demonstrated an elevation of MHCII expression on Ly6Chi iMo
in the BM early during L. donovani infection (15) by conducting
analysis into the chronic period of infection and though analysis
of the mechanisms responsible for this finding. Notably, we
demonstrate that the change seen in B6 mice in terms of MHCII
expression is a direct consequence of IFNg-signaling and in turn
that this IFNg is produced predominately by CD4+ T cells and
opposed by IL-10.
Through independent experimental approaches using gene
targeted mice and mAb blockade, we have provided evidence
that IL-10 impacts on the activation status of BM monocytes
during L. donovani infection. Although IL-10 production by
splenic CD25- Foxp3- CD4+ T cells has been reported to correlate
with disease progression in experimental VL (35, 36), in the BMwe
found no evidence that CD4+ (or CD8+) T cells produced
appreciably levels of IL-10 over 8 weeks course of infection
(Figure 2A). This finding is in accord with the notion that the
CD4+Tcell population recruited to theBMduring infectionmaybe
selected for IFNg production (16). In the absence of IL-10
production by T cells, other cellular sources are therefore
implicated. In spleen and liver, these have been shown to include
NK cells (37) and CD11chi conventional dendritic cells (36) in
addition to macrophages and monocytes themselves (38–41).
Furthermore, innate activation of B cells to produce IL-10 has
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FIGURE 5 | The presence of L. donovani parasites in the BM is necessary to maintain monocyte activation. (A–E) B6.Il10-/- mice were re-infected (RI) at d56 with
3x107 L. donovani amastigotes and killed 1 day post re-infection. (A) Experimental strategy. (B) Parasite load per one million cells determined by limiting dilution
assay in the BM at day 56 or 1 day post RI. Mann-Whitney test applied: P=0.006 (**); 95% CI: 87.73 – 200; statistical power: 100%; n=7. (C) Percentage of MHCII
on Ly6C+CCR2+ monocytes in the BM. Brown-Forsythe ANOVA applied only to day 56 data: P=0.0019; statistical power: 99.5%; n≥3; post hoc test Dunnett’s T3:
statistical difference reached in B6.wt vs. B6.il10-/- (P=0.0073; **); 95% CI: 5.06 – 44.58) and B6.il10-/- vs. B6.il10-/- RI (P=0.0024; **); 95% CI: -51.32 – -12.13).
(D) Level of MHCII expressed by the BM Ly6C+CCR2+ monocytes represented on histogram. (E) MFI of MHCII on Ly6C+CCR2+ monocytes in the BM of the
indicated mice. Brown-Forsythe ANOVA applied only to day 56 data: P=0.0019; statistical power: 26.7%; n≥3; post hoc test Dunnett’s T3: statistical difference
reached in B6.wt vs. B6.il10-/- RI (P=0.0006; ***); 95% CI: -4297 – -1310) and B6.il10-/- vs. B6.il10-/- RI (P=0.0002: ***); 95% CI: -5099 – -2266). (F–H) B6 mice
infected for 28 days were treated with 10mg/kg of Ambisome®. Data were collected 3 days post-treatment. (F) Parasite load measured by limiting dilution assay in
the BM. Welch’s t test applied in (F) P<0.0001; ****; 95% CI: -3.31 – -1.67; statistical power: 100%; n≥6. Percentage (G) and MFI (H) of MHCII expressed on
Ly6C+CCR2+ monocytes. Brown-Forsythe ANOVA applied in (G): P<0.0001; statistical power: 100%; n≥3; post hoc test Dunnett’s T3: statistical difference reached in all
pairs (P<0.0001; ****); and Kruskal-Wallis test applied in (H): P=0.0002; statistical power: 100%; n≥3; post hoc test Dunn’s MCT in Na+Amb vs. Inf (P=0.0071; **). In (A–E),
data are from 3 to 5 mice per group/experiment. Experiments were performed twice and pooled data are shown. In (F–H), data were derived from 3 to 4 mice/group.
Mean ± SD is shown except in A Median with 95% CI is shown.
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been demonstrated in the context of L. donovani infection (42) and
plasma cells producing IL-10 have been implicated in directing
myeloid cell differentiation under homeostatic conditions (43).
Further investigation with for example IL-10 transcriptional
reporter mice will be required to confirm the identity of the IL-
10-producing cells in theBMofL. donovani-infectedmice and their
relative roles in regulating monocyte activation.
In this study, we did not aim to directly assess the role of iMo
in disease outcome, a subject that has been studied by others.
Satoskar and colleagues have previously reported that iMo were
associated with enhanced parasite loads in the spleen of B6 mice
and that these iMo showed an activation profile biased at the
transcriptional level towards arginase production. In contrast,
iMo in the liver of these L. donovani-infected mice where more
biased towards iNOS production (44). Paradoxically, blockade of
iMo ingress to the spleen and liver using a CCR2 antagonist led
to improved host resistance in both tissues, suggesting that
phenotypic characteristics measured in vitro may not always
reflect in vivo function. In contrast, another study using CCR2-
deficient mice failed to demonstrate a role for iMo in host
resistance and hepatic granuloma formation (45). We have not
directly measured arginase in BM iMO in this study, but iNOS
production was clearly elevated throughout the course of
infection through a IFNg-dependent pathway, most likely
involving STAT1 signaling (44). Whilst this study also showed
that iMO in the peritoneal cavity could efficiently phagocytose
L. donovani amatigotes, they did not show that this directly
occurred at the major sites of infection. Abidin et al. (15)
demonstrated that alterations in myelopoiesis led to the
generation of regulatory iMO that suppress protective
immunity and these monocytes were identified to be
parasitized in the BM. Phenotypic changes in MHCII and
Ly6C expression suggested exposure to IFNg, in keeping with
our direct demonstration of a role for IFNgR signalling, but also
up-regulation of galectin-3, associated with alternate activation
(46). Further studies will be necessary to identify if changes in
monocyte activation affects anti-leishmanial immunity in other
sites of infection such as the spleen and the liver.
Our data also provide an in vivo example of the intimate
relationship between immune activation and parasite load.
Although IL-10 deficiency leads to a rapid acceleration and
augmentation of monocyte activation, this is transient and by
d56 post infection, monocyte activation in B6.Il10-/- mice has
returned to a homeostatic baseline. One explanation for this
apparently paradoxical observation is that maintenance of
monocyte activation and local IFNg production is dependent
upon the presence of parasites in the BM environment, a
suggestion borne out by experimentation. Thus, reduction of
parasite load by drug treatment rapidly reduced expression of
MHCII on BMmonocytes whereas reinfection of previously cured
B6.Il10-/- mice with L. donovani led to a rapid increase in BM
monocyte MHCII expression. Similarly, adoptive transfer of CD4+
T cells from infected mice into naïve recipient hosts does not lead
to monocyte activation, indicating a need for parasites to trigger
this response in BMmonocytes. The lack of monocyte activation in
the BM of infected B6.Rag2-/-mice suggests that parasites alone are
not sufficient for such activation. Rather, IFNg-producing CD4+ T
cells and Leishmania are both required to induce this response.
Currently, we cannot distinguish between a model in which
parasite antigens contribute to CD4+ T cell activation through
cognate pathways of antigen presentation or one in which parasites
induce bystander CD4+ T cell activation through innate (e.g. TLR)
signaling pathways. Alternatively, parasites and or their products
may directly stimulate monocytes through similar engagement
of pattern recognition receptors, though this itself is insufficient
to drive MHCII and iNOS expression in the absence of T cell-
derived IFNg. Nevertheless, our data clearly demonstrate the
importance of parasite load as a parameter influencing local
immunoregulatory pathways.
Whilst the kinetics of induction ofMHCII expression following
T cell activation was expected based on the known role of IFNg in
the transcriptional regulationofMHCII expressiononmyeloidcells
(47), the rapid change seen after pathogen clearance with
AmBisome® in terms of both the frequency of MHCII+ BM
monocytes and the abundance of MHCII was surprising. One
explanation for a reduced frequency of MHCII+ monocytes is
that MHCIIhi iMo are released from the BM as a consequence of
a change in the balance of retention/egress signals (48) and that
newly produced monocytes fail to become activated. CXCL12, the
ligand for the main retention receptor CXCR4, is produced locally
by BM and splenic stromal cells but expression is reduced at the
mRNA and protein level in these tissues as well as in the BM
following L. donovani infection (17, 49–51). In contrast, the
monocyte attracting chemokines CCL2, CCL7 and CCL8 remain
highly expressed in spleen (51) and splenic CCL2 mRNA
accumulation remains elevated even after AmBisome® treatment
(52). Alternatively, the more marked reduction in MFI for MHCII
on BMmonocytes is suggestive of cell intrinsic changes in protein
expression. E3 ubiquitin ligases of theMARCH family play a role in
regulating cell surface expression of a variety ofmembrane proteins
(53). Of note, MARCH1 plays a central role in IL-10-mediated
post translational regulation of surface MHCII expression in
human monocytes and other myeloid cells (54, 55), in addition to
regulating monocyte differentiation (56). Additional studies would
be needed to further dissect this novel aspect of monocyte MHCII
expression following parasite clearance.
In summary, we have demonstrated that BM monocyte
activation is a prominent feature of L. donovani infection in
mice and reflects the outcome of an intricate balance between
IFNg, IL-10 and parasite load. Little is currently known about the
role of BM monocytes in the progression of human VL and
during the response of patients to therapy. The studies outlined
here, together with the relative ease and safety with which bone
marrow aspirates can be obtained from VL patients, provide a
foundation to explore in more detail this aspect of myeloid cell
function during human VL.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.
Romano et al. Monocyte Activation in Visceral Leishmaniasis
Frontiers in Immunology | www.frontiersin.org September 2021 | Volume 12 | Article 70050110
ETHICS STATEMENT
The animal studies were carried out in accordance with the
Animals and Scientific Procedures Act 1986, under UK Home
Office Licence (project licence number PPL 60/4377 approved
by the University of York Animal Welfare and Ethics
Review Board).
AUTHOR CONTRIBUTIONS
Conceptualization: AR and PMK. Data curation: AR and PMK.
Formal analysis: AR and JD. Funding acquisition: PMK.
Investigation: GA, NB, HA, JD, JH, MO, ND, GR, and TF.
Methodology: AR and PMK. Project administration: PMK.
Resources: PMK. Supervision: PMK. Visualization: AR. Writing,
original draft: AR and PMK. Writing, review and editing: AR and
PMK. All authors contributed to the article and approved the
submitted version.
FUNDING
This work was funded by a Wellcome Trust Senior Investigator
Award to PMK (WT104726).
ACKNOWLEDGMENTS
The authors thank the staff of the Biological Services Facility and
Biosciences Technology Facility for their support in animal
husbandry and flow cytometry, respectively.
SUPPLEMENTARY MATERIAL




1. Yanez A, Coetzee SG, Olsson A, Muench DE, Berman BP, Hazelett DJ, et al.
Granulocyte-Monocyte Progenitors and Monocyte-Dendritic Cell
Progenitors Independently Produce Functionally Distinct Monocytes.
Immunity (2017) 47(5):890–902.e4. doi: 10.1016/j.immuni.2017.10.021
2. Terry RL, Miller SD. Molecular Control of Monocyte Development. Cell
Immunol (2014) 291(1-2):16–21. doi: 10.1016/j.cellimm.2014.02.008
3. Jakubzick CV, Randolph GJ, Henson PM. Monocyte Differentiation and
Antigen-Presenting Functions. Nat Rev Immunol (2017) 17(6):349–62.
doi: 10.1038/nri.2017.28
4. Zigmond E, Varol C. Two Roads Diverge in the Sick Liver, Monocytes
Travel Both. Immunity (2020) 53(3):479–81. doi: 10.1016/j.immuni.
2020.08.006
5. Zigmond E, Varol C, Farache J, Elmaliah E, Satpathy AT, Friedlander G, et al.
Ly6C Hi Monocytes in the Inflamed Colon Give Rise to Proinflammatory
Effector Cells and Migratory Antigen-Presenting Cells. Immunity (2012) 37
(6):1076–90. doi: 10.1016/j.immuni.2012.08.026
6. Menezes S, Melandri D, Anselmi G, Perchet T, Loschko J, Dubrot J, et al. The
Heterogeneity of Ly6C(hi) Monocytes Controls Their Differentiation Into
iNOS(+) Macrophages or Monocyte-Derived Dendritic Cells. Immunity
(2016) 45(6):1205–18. doi: 10.1016/j.immuni.2016.12.001
7. Askenase MH, Han SJ, Byrd AL, Morais da Fonseca D, Bouladoux N,
Wilhelm C, et al. Bone-Marrow-Resident NK Cells Prime Monocytes for
Regulatory Function During Infection. Immunity (2015) 42(6):1130–42.
doi: 10.1016/j.immuni.2015.05.011
8. Park J, Hunter CA. The Role of Macrophages in Protective and Pathological
Responses to Toxoplasma Gondii. Parasite Immunol (2020) 42(7):e12712.
doi: 10.1111/pim.12712
9. Serbina NV, Pamer EG. Monocyte Emigration From Bone Marrow During
Bacterial Infection Requires Signals Mediated by Chemokine Receptor CCR2.
Nat Immunol (2006) 7(3):311–7. doi: 10.1038/ni1309
10. Zhu J, Chen H, Huang X, Jiang S, Yang Y. Ly6C(hi) Monocytes Regulate T
Cell Responses in Viral Hepatitis. JCI Insight (2016) 1(17):e89880.
doi: 10.1172/jci.insight.89880
11. Romano A, Carneiro MBH, Doria NA, Roma EH, Ribeiro-Gomes FL, Inbar E,
et al. Divergent Roles for Ly6C+CCR2+CX3CR1+ Inflammatory Monocytes
During Primary or Secondary Infection of the Skin With the Intra-Phagosomal
Pathogen Leishmania Major. PloS Pathog (2017) 13(6):e1006479. doi: 10.1371/
journal.ppat.1006479
12. Leon B, Lopez-Bravo M, Ardavin C. Monocyte-Derived Dendritic Cells
Formed at the Infection Site Control the Induction of Protective T Helper 1
Responses Against Leishmania. Immunity (2007) 26(4):519–31. doi: 10.1016/
j.immuni.2007.01.017
13. Montes de Oca M, Engwerda CR, Kaye PM. Cytokines and Splenic
Remodelling During Leishmania Donovani Infection. Cytokine X (2020) 2
(4):100036. doi: 10.1016/j.cytox.2020.100036
14. Yurdakul P, Dalton J, Beattie L, Brown N, Erguven S, Maroof A, et al.
Compartment-Specific Remodeling of Splenic Micro-Architecture During
Experimental Visceral Leishmaniasis. Am J Pathol (2011) 179(1):23–9.
doi: 10.1016/j.ajpath.2011.03.009
15. Abidin BM, Hammami A, Stager S, Heinonen KM. Infection-Adapted
Emergency Hematopoiesis Promotes Visceral Leishmaniasis. PloS Pathog
(2017) 13(8):e1006422. doi: 10.1371/journal.ppat.1006422
16. Pinto AI, Brown N, Preham O, Doehl JSP, Ashwin H, Kaye PM. TNF
Signalling Drives Expansion of Bone Marrow CD4+ T Cells Responsible for
HSC Exhaustion in Experimental Visceral Leishmaniasis. PloS Pathog (2017)
13(7):e1006465. doi: 10.1371/journal.ppat.1006465
17. Preham O, Pinho FA, Pinto AI, Rani GF, Brown N, Hitchcock IS, et al. CD4
(+) T Cells Alter the Stromal Microenvironment and Repress Medullary
Erythropoiesis in Murine Visceral Leishmaniasis. Front Immunol (2018)
9:2958. doi: 10.3389/fimmu.2018.02958
18. Sokal RR, Rohlf JF. Biometry: The Principles and Practice of Statistics in
Biological Research. 2nd ed. San Francisco: W.H. Freeman (1981).
19. Mair P, Wilcox R. Robust Statistical Methods in R Using the WRS2 Package.
Behav Res Methods (2020) 52(2):464–88. doi: 10.3758/s13428-019-01246-w
20. Lenth RV. Emmeans: Estimated Marginal Means, Aka Least-Squares Means. R
Package. 1.6.1. (2021). Available at: https://CRAN.R-project.org/package=
emmeans.
21. Champely S. Pwr: Basic Functions for Power Analysis. R Package Version. 1.3-
0. (2020). Available at: https://CRAN.R-project.org/package=pwr.
22. Lu P, Liu J, Koestler D. Pwr2: Power and Sample Size Analysis for One-Way
and Two-Way ANOVA Models. R Package Version 1.0. (2017). Available at:
https://CRAN.R-project.org/package=pwr2.
23. Wickham H, Bryan J. Readxl: Read Excel Files. R Package 1.3.1. (2019).
Available at: https://CRAN.R-project.org/package=readxl.
24. Dragulescu A, Arendt C. Xlsx: Read, Write, Format Excel 2007 and Excel 97/
2000/XP/2003 Files Version. 0.6.5. (2020). Available at: https://CRAN.R-
project.org/package=xlsx.
25. Ren K. Rlist: A Toolbox for Non-Tabular Data Manipulation. 0.4.6.1 (2016).
Available at: https://CRAN.R-project.org/package=rlist.
26. Firke S. Janitor: Simple Tools for Examining and Cleaning Dirty Data. 2.1.0.
(2021). Available at: https://CRAN.R-project.org/package=janitor.
27. Kassambara A. Rstatix: Pipe-Friendly Framework for Basic Statistical Tests.
0.7.0. (2021). Available at: https://CRAN.R-project.org/package=rstatix.
28. Fox J, Weisberg S. An {R} Companion to Applied Regression. California:
Thousand Oaks (2019). Available at: https://socialsciences.mcmaster.ca/jfox/
Books/Companion/.
Romano et al. Monocyte Activation in Visceral Leishmaniasis
Frontiers in Immunology | www.frontiersin.org September 2021 | Volume 12 | Article 70050111
29. Komsta L, Novometsky F.Moments: Moments, Cumulants, Skewness, Kurtosis
and Related Tests. Version 0.14. (2015). Available at: https://CRAN.R-project.
org/package=moments.
30. Wickham H. Reshaping Data With the Reshape Package. J Stat Software
(2007) 21(12):1–20.
31. Shachar B, Ludecke M, Makowski D. Effectsize: Estimation of Effect Size
Indices and Standardized Parameters. J Open Source Software (2020) 5
(56):2815. doi: 10.21105/joss.02815
32. Wickham H. Welcome to the Tidyverse. J Open Source Software (2019) 4
(43):1686. doi: 10.21105/joss.01686
33. MooreKW,O’GarraA, deWaalMalefyt R,Vieira P,MosmannTR. Interleukin-10.
Annu Rev Immunol (1993) 11:165–90. doi: 10.1146/annurev.iy.11.040193.001121
34. MurphyML,WilleU,VillegasEN,HunterCA,Farrell JP. IL-10MediatesSusceptibility
to Leishmania Donovani Infection. Eur J Immunol (2001) 31(10):2848–56.
doi: 10.1002/1521-4141(2001010)31:10<2848::aid-immu2848>3.0.co;2-t
35. Stager S, Maroof A, Zubairi S, Sanos SL, Kopf M, Kaye PM. Distinct Roles for
IL-6 and IL-12p40 in Mediating Protection Against Leishmania Donovani and
the Expansion of IL-10+ CD4+ T Cells. Eur J Immunol (2006) 36(7):1764–71.
doi: 10.1002/eji.200635937
36. Owens BM, Beattie L, Moore JW, Brown N, Mann JL, Dalton JE, et al. IL-10-
Producing Th1 Cells and Disease Progression Are Regulated by Distinct
CD11c(+) Cell Populations During Visceral Leishmaniasis. PloS Pathog
(2012) 8(7):e1002827. doi: 10.1371/journal.ppat.1002827
37. Maroof A, Beattie L, Zubairi S, Svensson M, Stager S, Kaye PM.
Posttranscriptional Regulation of II10 Gene Expression Allows Natural
Killer Cells to Express Immunoregulatory Function. Immunity (2008) 29
(2):295–305. doi: 10.1016/j.immuni.2008.06.012
38. Chandra D, Naik S. Leishmania Donovani Infection Down-Regulates TLR2-
Stimulated IL-12p40 and Activates IL-10 in Cells of Macrophage/Monocytic
Lineage by Modulating MAPK Pathways Through a Contact-Dependent
Mechanism. Clin Exp Immunol (2008) 154(2):224–34. doi: 10.1111/j.1365-
2249.2008.03741.x
39. Kong F, Saldarriaga OA, Spratt H, Osorio EY, Travi BL, Luxon BA, et al.
Transcriptional Profiling in Experimental Visceral Leishmaniasis Reveals a Broad
Splenic Inflammatory Environment That Conditions Macrophages Toward a
Disease-Promoting Phenotype. PloS Pathog (2017) 13(1):e1006165. doi: 10.1371/
journal.ppat.1006165
40. Parmar N, Chandrakar P, Kar S. Leishmania Donovani Subverts Host
Immune Response by Epigenetic Reprogramming of Macrophage M
(Lipopolysaccharides + IFN-Gamma)/M(IL-10) Polarization. J Immunol
(2020) 204(10):2762–78. doi: 10.4049/jimmunol.1900251
41. Roy S,MukhopadhyayD,Mukherjee S,Moulik S, Chatterji S, BrahmeN, et al. An
IL-10 Dominant Polarization of Monocytes Is a Feature of Indian Visceral
Leishmaniasis. Parasite Immunol (2018) 40(7):e12535. doi: 10.1111/pim.12535
42. Silva-Barrios S, Smans M, Duerr CU, Qureshi ST, Fritz JH, Descoteaux A,
et al. Innate Immune B Cell Activation by Leishmania Donovani Exacerbates
Disease and Mediates Hypergammaglobulinemia. Cell Rep (2016) 15
(11):2427–37. doi: 10.1016/j.celrep.2016.05.028
43. Meng L, Almeida LN, Clauder AK, Lindemann T, Luther J, Link C, et al. Bone
Marrow Plasma Cells Modulate Local Myeloid-Lineage Differentiation via IL-
10. Front Immunol (2019) 10:1183. doi: 10.3389/fimmu.2019.01183
44. Terrazas C,Varikuti S, Oghumu S, SteinkampHM,Ardic N,Kimble J, et al. Ly6C
(hi) Inflammatory Monocytes Promote Susceptibility to Leishmania Donovani
Infection. Sci Rep (2017) 7(1):14693. doi: 10.1038/s41598-017-14935-3
45. SatoN,KuzielWA,MelbyPC, ReddickRL,KosteckiV, ZhaoW, et al. Defects in the
Generation of IFN-Gamma Are Overcome to Control Infection With Leishmania
Donovani in CC Chemokine Receptor (CCR) 5-, Macrophage Inflammatory
Protein-1 Alpha-, or CCR2-Deficient Mice. J Immunol (1999) 163(10):5519–25.
46. MacKinnon AC, Farnworth SL, Hodkinson PS, Henderson NC, Atkinson KM,
Leffler H, et al. Regulation of Alternative Macrophage Activation by Galectin-3.
J Immunol (2008) 180(4):2650–8. doi: 10.4049/jimmunol.180.4.2650
47. Reith W, Muhlethaler-Mottet A, Masternak K, Villard J, Mach B. The
Molecular Basis of MHC Class II Deficiency and Transcriptional Control of
MHC Class II Gene Expression. Microbes Infect (1999) 1(11):839–46.
doi: 10.1016/s1286-4579(99)00235-x
48. Teh YC, Ding JL, Ng LG, Chong SZ. Capturing the Fantastic Voyage of
Monocytes Through Time and Space. Front Immunol (2019) 10:834.
doi: 10.3389/fimmu.2019.00834
49. Nguyen Hoang AT, Liu H, Juarez J, Aziz N, Kaye PM, Svensson M. Stromal
Cell-Derived CXCL12 and CCL8 Cooperate to Support Increased
Development of Regulatory Dendritic Cells Following Leishmania Infection.
J Immunol (2010) 185(4):2360–71. doi: 10.4049/jimmunol.0903673
50. Svensson M, Kaye PM. Stromal-Cell Regulation of Dendritic-Cell
Differentiation and Function. Trends Immunol (2006) 27(12):580–7.
doi: 10.1016/j.it.2006.10.006
51. Ashwin H, Seifert K, Forrester S, Brown N, MacDonald S, James S, et al. Tissue
and Host Species-Specific Transcriptional Changes in Models of Experimental
Visceral Leishmaniasis. Wellcome Open Res (2018) 3:135. doi: 10.12688/
wellcomeopenres.14867.2
52. Forrester S, Siefert K, Ashwin H, Brown N, Zelmar A, James S, et al. Tissue-
Specific Transcriptomic Changes Associated With AmBisome(R) Treatment
of BALB/c Mice With Experimental Visceral Leishmaniasis. Wellcome Open
Res (2019) 4:198. doi: 10.12688/wellcomeopenres.15606.1
53. Ohmura-Hoshino M, Goto E, Matsuki Y, Aoki M, Mito M, Uematsu M, et al.
A Novel Family of Membrane-Bound E3 Ubiquitin Ligases. J Biochem (2006)
140(2):147–54. doi: 10.1093/jb/mvj160
54. Thibodeau J, Bourgeois-Daigneault MC, Huppe G, Tremblay J, Aumont A,
Houde M, et al. Interleukin-10-Induced MARCH1 Mediates Intracellular
Sequestration of MHC Class II in Monocytes. Eur J Immunol (2008) 38
(5):1225–30. doi: 10.1002/eji.200737902
55. Mittal SK, Cho KJ, Ishido S, Roche PA. Interleukin 10 (IL-10)-Mediated
Immunosuppression: March-I Induction Regulates Antigen Presentation By
Macrophages But Not Dendritic Cells. J Biol Chem (2015) 290(45):27158–67.
doi: 10.1074/jbc.M115.682708
56. Galbas T, Raymond M, Sabourin A, Bourgeois-Daigneault MC, Guimont-
Desrochers F, Yun TJ, et al. MARCH1 E3 Ubiquitin Ligase Dampens the
Innate Inflammatory Response by Modulating Monocyte Functions in Mice.
J Immunol (2017) 198(2):852–61. doi: 10.4049/jimmunol.1601168
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Publisher’s Note: All claims expressed in this article are solely those of the authors
and do not necessarily represent those of their affiliated organizations, or those of
the publisher, the editors and the reviewers. Any product that may be evaluated in
this article, or claim that may be made by its manufacturer, is not guaranteed or
endorsed by the publisher.
Citation: Romano A, Brown N, Ashwin H, Doehl JSP, Hamp J, Osman M, Dey N,
Rani GF, Ferreira TR and Kaye PM (2021) Interferon-g-Producing CD4+ T Cells
Drive Monocyte Activation in the Bone Marrow During Experimental Leishmania
donovani Infection.
Front. Immunol. 12:700501. doi: 10.3389/fimmu.2021.700501
Copyright © 2021 Romano, Brown, Ashwin, Doehl, Hamp, Osman, Dey, Rani,
Ferreira and Kaye. This is an open-access article distributed under the terms of the
Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal is
cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Romano et al. Monocyte Activation in Visceral Leishmaniasis
Frontiers in Immunology | www.frontiersin.org September 2021 | Volume 12 | Article 70050112
